JP2020532509A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532509A5 JP2020532509A5 JP2020511473A JP2020511473A JP2020532509A5 JP 2020532509 A5 JP2020532509 A5 JP 2020532509A5 JP 2020511473 A JP2020511473 A JP 2020511473A JP 2020511473 A JP2020511473 A JP 2020511473A JP 2020532509 A5 JP2020532509 A5 JP 2020532509A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- seq
- cancer
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552345P | 2017-08-30 | 2017-08-30 | |
| US62/552,345 | 2017-08-30 | ||
| US201762553098P | 2017-08-31 | 2017-08-31 | |
| US62/553,098 | 2017-08-31 | ||
| US201762554919P | 2017-09-06 | 2017-09-06 | |
| US62/554,919 | 2017-09-06 | ||
| PCT/US2018/048965 WO2019046652A1 (en) | 2017-08-30 | 2018-08-30 | ANTI-CD166 ACTIVABLE ANTIBODIES, AND METHODS OF USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532509A JP2020532509A (ja) | 2020-11-12 |
| JP2020532509A5 true JP2020532509A5 (enExample) | 2021-10-21 |
Family
ID=63678683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511473A Pending JP2020532509A (ja) | 2017-08-30 | 2018-08-30 | 活性化可能抗ｃｄ１６６抗体およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190117789A1 (enExample) |
| EP (1) | EP3676293A1 (enExample) |
| JP (1) | JP2020532509A (enExample) |
| KR (1) | KR20200058406A (enExample) |
| CN (1) | CN111212853A (enExample) |
| AU (1) | AU2018324097A1 (enExample) |
| BR (1) | BR112020004231A2 (enExample) |
| CA (1) | CA3074112A1 (enExample) |
| IL (1) | IL272703A (enExample) |
| MX (1) | MX2020002198A (enExample) |
| SG (1) | SG11202001173VA (enExample) |
| WO (1) | WO2019046652A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017023872A2 (pt) | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| BR112021008526A2 (pt) * | 2018-11-02 | 2021-08-10 | Cytomx Therapeutics, Inc. | anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| EP4504782A2 (en) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| US20260015425A1 (en) | 2022-08-01 | 2026-01-15 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| CN120958015A (zh) | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4694934A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5030719A (en) | 1986-08-28 | 1991-07-09 | Teijin Limited | Cytotoxic antibody conjugates and a process for preparation thereof |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| WO2007027935A2 (en) | 2005-08-31 | 2007-03-08 | The Regents Of The University Of California | Cellular libraries of peptide sequences (clips) and methods of using the same |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| WO2010129609A2 (en) | 2009-05-07 | 2010-11-11 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| WO2013011931A1 (ja) * | 2011-07-20 | 2013-01-24 | 株式会社 村田製作所 | 全固体電池およびその製造方法 |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| HK1219422A1 (zh) * | 2013-02-28 | 2017-04-07 | Immunogen, Inc. | 包含细胞结合剂及细胞毒素剂的轭合物 |
| US9626054B2 (en) * | 2014-12-19 | 2017-04-18 | Salt International Corp. | Capacitive sensing device and method that reduces influence from transient environmental changes |
| BR112017023872A2 (pt) * | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
-
2018
- 2018-08-30 CN CN201880066681.8A patent/CN111212853A/zh active Pending
- 2018-08-30 AU AU2018324097A patent/AU2018324097A1/en not_active Abandoned
- 2018-08-30 CA CA3074112A patent/CA3074112A1/en active Pending
- 2018-08-30 JP JP2020511473A patent/JP2020532509A/ja active Pending
- 2018-08-30 MX MX2020002198A patent/MX2020002198A/es unknown
- 2018-08-30 EP EP18773905.7A patent/EP3676293A1/en not_active Withdrawn
- 2018-08-30 SG SG11202001173VA patent/SG11202001173VA/en unknown
- 2018-08-30 US US16/118,295 patent/US20190117789A1/en not_active Abandoned
- 2018-08-30 WO PCT/US2018/048965 patent/WO2019046652A1/en not_active Ceased
- 2018-08-30 KR KR1020207008316A patent/KR20200058406A/ko not_active Ceased
- 2018-08-30 BR BR112020004231-5A patent/BR112020004231A2/pt not_active IP Right Cessation
-
2020
- 2020-02-16 IL IL272703A patent/IL272703A/en unknown
- 2020-07-21 US US16/934,955 patent/US20210100913A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers | |
| JP2022512920A5 (enExample) | ||
| Caniglia et al. | A potential role for Galectin-3 inhibitors in the treatment of COVID-19 | |
| Jay et al. | An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential | |
| CN109891245B (zh) | 自身免疫疾病的诊断、预防和/或治疗 | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2020534352A5 (enExample) | ||
| JP2020510662A5 (enExample) | ||
| FI4074331T3 (fi) | Koostumuksia ja menetelmiä entsyymien internalisoimiseksi | |
| Kollmorgen et al. | Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy | |
| JP2020517658A5 (enExample) | ||
| JP2014523884A5 (enExample) | ||
| JP2020513855A5 (enExample) | ||
| JP2015516813A5 (enExample) | ||
| JP2016525551A5 (enExample) | ||
| JP2012529891A5 (enExample) | ||
| WO2016180034A1 (zh) | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 | |
| WO2020132366A4 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| JP2019501973A5 (enExample) | ||
| JP2022513421A5 (enExample) | ||
| JP2019520038A5 (enExample) | ||
| US20170029531A1 (en) | Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells | |
| US20160206691A1 (en) | Treatment of tumours using peptide-protein conjugates | |
| Santoni et al. | Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma | |
| JP2020508066A5 (enExample) |